ADELAIDE , South Australia , Sept. 24, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with drug developer EnGeneIC Pty Ltd.
, for a project including technology transfer, process scale-up and GMP batch manufacture of EnGeneIC's proprietary 'EnGeneIC Dream Vector' (EDV TM ) nanocells. EnGeneIC's mission is to transform cancer treatment through targeted cyto-immunotherapy by developing Antibody-Nanocell Drug Conjugates (ANDCs) using its EDV TM platform, which employs antibody-targeted, non-living 'nanocells' to deliver cytotoxic payloads directly into tumor cells. ANDCs enable the use of highly potent chemotherapeutic drugs encapsulated by nanocells, thereby reducing systemic toxicity, while also offering a new means for treating drug-resistant cancers and stimulating a potent anti-cancer immune response.
This dual approach aims at safer, more targeted treatments with fewer side effects, for patients with nowhere else to turn. BioCina will deliver an end-to-end package of services in preparation for clinical and commercial manufacture of EDVs. BioCina's Chief Executive Officer, Mark W.
Womack stated, "I'm so very proud for BioCina to be entrusted to advance EnGeneIC's transformative therapeutic, which has the potential to make a profound impact on previously untreatable cancers." EnGeneIC's Co-Founder and CEO, Dr. Himanshu Brahmbhatt stated, "For several years, EnGeneIC .
